Company Information
Industry 制造业
Company Introduction 杭州天目山药业股份有限公司(600671.SH)始于1958年,1993年在上交所上市,是杭州第一家上市公司,也是中国中药制剂第一股。公司聚焦中医药产业,现有药品制造、药品流通、中医诊疗、大健康四大业务板块。 公司下设临安制药中心、黄山天目、黄山薄荷三大生产基地,现有各类药品制剂批准文号98个、保健品批准文号5个,涵盖片剂、颗粒、胶囊、软胶囊、口服液、糖浆、丸剂等剂型,其中珍珠明目滴眼液、六味地黄口服液、河车大造胶囊、安眠补脑颗粒等产品闻名全国。 黄山薄荷生产的“黄山牌”薄荷脑、薄荷油市场份额居前,供应国内多家知名制药、日化企业;控股子公司“三慎泰”中医门诊部,汇聚众多名老中医打造特色中西诊疗。 天目药业历史悠久,旗下拥有“天目山”、“新安江”两大知名品牌。“天目山牌铁皮石斛”被列为“国家地理标志保护产品”,享誉国内外;“天目山中药文化”被列为浙江省非物质文化遗产名录。 中医药作为中华民族的瑰宝,“治未病”也逐步成为国家战略。在国家大力推进中医药发展趋势下,新一届天目股东和管理团队制定了新的发展战略——增加优势产品产能,扩大特色产品影响力,围绕大健康产业布局赋能。 目前,公司积极拓展“新中药”事业,激发传统中药的现代活力。同时,借助丰富的中医药行业资源,通过药方改良、专家合作等多种方式,打造一系列以养生和调理为目标的药食同源大健康产品,惠及百姓健康。 “让生活更美好”,天目药业正以崭新的面貌助推祖国中医药文化更创辉煌。
Main Business 生物制药、中成药、西药、保健品、电子产品、机制纸的制造和销售,商业贸易和摊位出租。
Legal Representative 刘加勇
Top Executives
董事长:刘加勇
副董事长:党国峻
董事:刘士彬,黄俊德,刘加勇,于鸿坚,贾云松
独立董事:聂学民,盛筱艨,裴阳
Top 5 Shareholder
Shareholder name Nature Holding Date
青岛汇隆华泽投资有限公司流通A股29.99%30/09/2024
青岛源嘉医疗科技有限公司流通A股12.57%30/09/2024
浙江清风原生文化有限公司流通A股4.26%30/09/2024
杭州岳殿润投资管理合伙企业(有限合伙)流通A股3.28%30/09/2024
李俊凤流通A股2.26%30/09/2024
Company Secretary 党国峻
Solicitors 浙江省经济律师事务所
Auditors 浙江省会计师事务所
Tel No 0571-63722229
Fax No 0571-63715400
Website www.hztmyy.com
Email tianmuyaoye@126.com
Company Address
Register: 浙江省杭州市临安区锦南街道上杨路18号
Office: 浙江省杭州市萧山区盈丰街道市心北路博亚时代中心1803-1804
Listing Date 23/08/1993
Shares Capital
Shares Capital: 121,778,885
Total A Share: 121,778,885
Listed A Share: 121,720,533
Non-tradable A Share: 58,352
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.314
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 0.305
Market Capitalization(RMB) 1.166B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.